Octanate (Human Coagulation Factor Viii)

Human Coagulation Factor VIII, the active ingredient in Octanate, is a coagulation factor replacement therapy presented as a intravenous solution for intravenous use. It treats hemophilia A by providing the missing clotting protein in patients with this inherited bleeding disorder. GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Octanate is used in the management of bleeding disorders that involve the intrinsic coagulation pathway, particularly hemophilia A. - Hemophilia A (severe): Provides factor VIII activity to prevent or control spontaneous bleeding episodes. - Hemophilia A (moderate): Increases factor VIII levels to reduce the frequency of bleeding events. - Hemophilia A (mild): Supplements low endogenous factor VIII to achieve hemostasis during surgery or trauma. - Acquired hemophilia A – Provides supplement of factor VIII to control bleeding in auto‑immune mediated cases.

Octanate may elicit adverse reactions that vary in frequency and severity.

Common Side Effects: -  C  ...